Exeter Financial LLC Buys 85 Shares of Amgen Inc. (NASDAQ:AMGN)

Exeter Financial LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 0.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,079 shares of the medical research company’s stock after buying an additional 85 shares during the period. Amgen comprises about 1.5% of Exeter Financial LLC’s investment portfolio, making the stock its 24th biggest position. Exeter Financial LLC’s holdings in Amgen were worth $3,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen during the 4th quarter valued at $29,000. United Community Bank bought a new position in shares of Amgen during the 4th quarter valued at $29,000. Planned Solutions Inc. bought a new position in shares of Amgen during the 4th quarter valued at $30,000. Delos Wealth Advisors LLC grew its holdings in shares of Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares during the last quarter. Finally, Hartford Financial Management Inc. grew its holdings in shares of Amgen by 56.9% during the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several analyst reports. Mizuho increased their price target on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Morgan Stanley increased their price target on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, May 3rd. Finally, Royal Bank of Canada increased their price target on shares of Amgen from $328.00 to $332.00 and gave the company an “outperform” rating in a research report on Friday, June 14th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $305.85.

Amgen Stock Up 0.0 %

NASDAQ AMGN traded up $0.07 during trading hours on Thursday, reaching $312.89. 877,626 shares of the company’s stock traded hands, compared to its average volume of 2,775,602. Amgen Inc. has a 52-week low of $218.44 and a 52-week high of $329.72. The firm has a market cap of $167.84 billion, a PE ratio of 45.00, a PEG ratio of 2.88 and a beta of 0.60. The firm has a 50-day simple moving average of $299.67 and a 200 day simple moving average of $291.67. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $7.45 billion. During the same period last year, the company posted $3.98 EPS. Amgen’s revenue was up 22.0% on a year-over-year basis. Sell-side analysts anticipate that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.